Telix Pharmaceuticals Files ProstACT Global Study Update
Ticker: TLPPF · Form: 6-K · Filed: Dec 17, 2025 · CIK: 2007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLPPF) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, foreign-issuer, press-release
TL;DR
Telix Pharma dropped a 6-K on 12/17/25 with an update on their ProstACT Global Study.
AI Summary
On December 17, 2025, Telix Pharmaceuticals Limited announced the status of its ProstACT Global Study. The company filed this update as part of its Form 6-K with the SEC, attaching the press release as Exhibit 99.1.
Why It Matters
This filing provides an update on a key clinical study for Telix Pharmaceuticals, which could impact the future development and commercialization of their therapeutic products.
Risk Assessment
Risk Level: low — The filing is an informational update on a clinical study status and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- Telix Pharmaceuticals Limited (company) — Registrant
- ProstACT Global Study (study) — Subject of the announcement
- December 17, 2025 (date) — Date of filing and announcement
FAQ
What is the specific status update provided for the ProstACT Global Study?
The filing states that Telix Pharmaceuticals Limited announced the status of its ProstACT Global Study on December 17, 2025, but the specific details of the update are contained within Exhibit 99.1, which is a press release.
What form was filed with the SEC regarding this announcement?
Telix Pharmaceuticals Limited filed a Form 6-K with the SEC.
When was the announcement regarding the ProstACT Global Study made?
The announcement was made on December 17, 2025.
Where is Telix Pharmaceuticals Limited based?
Telix Pharmaceuticals Limited is based in North Melbourne, Victoria, Australia.
What exhibit contains the press release about the ProstACT Global Study?
Exhibit 99.1 contains the press release titled 'ProstACT Global Study Status' dated December 17, 2025.
Filing Stats: 228 words · 1 min read · ~1 pages · Grade level 14.8 · Accepted 2025-12-17 16:06:57
Filing Documents
- k6prostupdate.htm (6-K) — 11KB
- prostactpr17.htm (EX-99.1) — 20KB
- image1.gif (GRAPHIC) — 34KB
- 0002007191-25-000075.txt ( ) — 79KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Telix Pharmaceuticals Limited       Date: December 17, 2025 By: /s/ Genevieve Ryan     Name: Genevieve Ryan     Title: Company Secretary